The latest biotech news

cardiology astrazeneca novartis cardiovascular disease

News and Trends 5 Sep 2019

Top Cardiology Biotech News from the ESC Conference 2019

Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […]

September 5, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 5 Sep 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […]

September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Sep 2019

US Genomics Firm Combines with Curetis to Tackle Antibiotic Resistance

The German biotech Curetis has been combined with the US genomics company OpGen to pool their molecular diagnostics expertise in the fight against antibiotic resistance. “After more than one year of intensive discussions and negotiations for many months, it feels great to be able to announce the transaction today,” Oliver Schacht, the CEO of Curetis, […]

September 4, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Sep 2019

Gyroscope Targets Age-Related Blindness with €55M Series B

UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […]

September 3, 2019 - 2 minutesmins - By Helen Albert

cancer cell therapy immunotherapy achilles therapeutics

News and Trends 3 Sep 2019

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […]

September 3, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 29 Aug 2019

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

The French biotech HiFiBiO has raised €60M in a Series C round to finance the development of antibody drugs for cancer and autoimmune diseases based on its single-cell screening technology. HiFiBiO will use the money to accelerate the progress of its drugs to clinical trials, though it has not specified when it plans to begin […]

August 29, 2019 - 2 minutesmins - By Jonathan Smith

dendritic cell immunicum cancer immunotherapy cell therapy

News and Trends 29 Aug 2019

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

An off-the-shelf cancer immunotherapy developed by the Swedish biotech Immunicum has eradicated kidney tumors in 11% of treated patients compared with just 4% of patients given standard treatments in a phase II trial. Immunicum is developing a cell immunotherapy to treat metastatic renal cell carcinoma. This advanced form of kidney cancer is particularly hard to […]

August 29, 2019 - 3 minutesmins - By Jonathan Smith

imcyse type 1 diabetes insulin immunotherapy

News and Trends 28 Aug 2019

Type 1 Diabetes Immunotherapy Shows Promise in Phase I

An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

celgene immatics cancer cell immunotherapy

News and Trends 28 Aug 2019

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 27 Aug 2019

Swedish Ulcerative Colitis Treatment Makes Phase II Comeback

InDex Pharmaceuticals’ ulcerative colitis drug candidate has achieved positive phase IIb results, suggesting work to improve its dosage after a previous phase III failure was successful. The Swedish company tested different doses of the small molecule drug cobitolimod against a placebo in patients with the inflammatory bowel disease ulcerative colitis. The 213 patients in the […]

August 27, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Aug 2019

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research funding and make an equity investment in Themis Bioscience. In addition, Themis will be eligible to receive up to €200M in milestones, in addition to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Top Cardiology Biotech News from the ESC Conference 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

US Genomics Firm Combines with Curetis to Tackle Antibiotic Resistance

Gyroscope Targets Age-Related Blindness with €55M Series B

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

Type 1 Diabetes Immunotherapy Shows Promise in Phase I

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

Swedish Ulcerative Colitis Treatment Makes Phase II Comeback

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!